A year ago, DOJ moved to dismiss 11 qui tam False Claims Act actions brought by Venari Partners, LLC (doing business as National Health Care Analysis Group), over NHCA’s objections. Those motions, together with DOJ’s promise in late November 2018 to dismiss Gilead Sciences, Inc. v. United States ex rel. Campie on remand from the Supreme Court, were an indication that DOJ was executing on the Granston Memo’s directive to seek dismissals of meritless and burdensome qui tam cases. Decisions have now been issued in all 11 cases. And while courts adopted different views as to the appropriate standard of review, 10 of the 11 cases ultimately were dismissed.
Regulations, Compliance, & Enforcement
Trending Now
Mandatory Disclosure Rule Best Practices for Government Contractors • SBA Proposes Rollback of Social Disadvantage Presumption in 8(a) Program • New EO on Customs Enforcement Tightens Import Controls, Aims to Reduce Evasion • New Grant Regulations from OMB • The False Alignment Trap in Compliance Transformation
Granston Motions Prove to be Effective Tools Against Professional Relator in Nurse Educator Cases
rawf8 | Shutterstock
Track False Claims Act cases, audit trends, and compliance best practices with our Compliance & Enforcement newsletter, delivering up-to-the-minute intelligence Monday–Saturday — Subscribe here.